Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Serum Institute CEO sees AstraZeneca's COVID-19 vaccine as "very good" candidate

11/28/2020 | 11:22am EST
FILE PHOTO: Outbreak of the coronavirus disease (COVID-19) in Pune

MUMBAI/NEW DELHI (Reuters) - Serum Institute of India, the world's largest vaccine producer, sees AstraZeneca Plc's COVID-19 vaccine candidate as a "very good" option, giving it a major vote of confidence after some experts raised questions around its trial data.

Serum Institute of India (SII), which has partnered with the British drugmaker to conduct trials on its COVISHIELD vaccine in India and produce the vaccine candidate if it secures approval, plans to apply for an emergency use licence for the vaccine in the next two weeks, said SII's Chief Executive Adar Poonawalla.

"This vaccine is a very good one," said Poonawalla, via a virtual press briefing following Indian Prime Minister Narendra Modi's visit to SII's campus on Saturday.

"What we found with COVISHIELD in its global trial is there were zero hospitalisations, which means even if you do get infected you're not going to have a severe attack and secondly even those who got the disease were not infecting others," he said.

Poonawalla's comments come as a boost to AstraZeneca after some scientists raised doubts about the robustness of results showing the shot was 90% effective in a sub-group of trial participants who, by error initially, received a half dose followed by a full dose.

He also noted that the AstraZeneca vaccine, along with the vaccine from Novavax - the U.S. vaccine developer that SII has also partnered with - offered a significant edge over the vaccine candidates of certain rivals, which need to be stored at much lower temperatures.

"Both our vaccine candidates can be stored in 2 Celsius to 8 Celsius and India has lot of storage and infrastructure for that temperature range. It has slightly less storage capacity for -20 C and almost nothing for -70 C," said Poonawalla.

U.S. vaccine developers Moderna and Pfizer recently announced strong efficacy results on their respective vaccine candidates, but both of their vaccines need to be stored at very low temperatures that would present challenges for many developing economies.

Moderna has said its vaccine can be stored at normal fridge temperatures of 2 to 8 degrees Celsius for 30 days and it can be stored for up to 6 months at -20C. Pfizer's experimental vaccine must be stored at -70C over longer durations.

(Reporting by Euan Rocha and Nidhi Verma; Additional reporting by Shilpa Jamkhandikar; Editing by Alex Richardson and David Evans)

By Euan Rocha and Nidhi Verma

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.53% 7909 Delayed Quote.8.57%
MODERNA, INC. 3.35% 151.93 Delayed Quote.45.35%
NOVAVAX, INC. -3.27% 127.16 Delayed Quote.17.89%
PFIZER INC. 0.08% 37.31 Delayed Quote.1.36%
All news about ASTRAZENECA PLC
05:55aEU OFFICIAL : AstraZeneca pulls out of meeting with EU to discuss delayed vaccin..
04:50aSanofi to Collaborate With BioNTech on Coronavirus Vaccine Production -- Upda..
03:41aASTRAZENECA : is recognised as a Top Employer 2021 in South Africa and Kenya
03:15aBill Gates sees 6-8 month lag for poor countries to get COVID-19 shots
03:10aASTRAZENECA : is recognised as a Top Employer 2021 in South Africa and Kenya Bei..
01/26ASTRAZENECA : Two Months Behind COVID-19 Vaccine Production Schedule in EU, CEO ..
01/26ASTRAZENECA : Faces Lawsuit Over COVID-19 Vaccine Testing Debacle
01/26MARKET CHATTER : Japan to Buy 20,000 Freezers for $96 Million to Store COVID-19 ..
01/26ASTRAZENECA : Global COVID-19 cases surpass 100 million as nations tackle vaccin..
01/26ASTRAZENECA : Peru orders total lockdown across 10 states as second wave bites
More news
Financials (USD)
Sales 2020 26 379 M - -
Net income 2020 2 956 M - -
Net Debt 2020 13 464 M - -
P/E ratio 2020 43,7x
Yield 2020 2,58%
Capitalization 143 B 143 B -
EV / Sales 2020 5,95x
EV / Sales 2021 5,10x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 127,03 $
Last Close Price 109,27 $
Spread / Highest target 43,8%
Spread / Average Target 16,3%
Spread / Lowest Target -17,4%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON8.32%448 796
ROCHE HOLDING AG4.51%312 213
NOVARTIS AG0.81%214 457
PFIZER INC.1.36%207 384
MERCK & CO., INC.-1.89%203 035